Acute myeloid leukemia (AML) in Down syndrome (DS) children has several unique features including a predominance of the acute megakaryocytic leukemia (AMkL) phenotype, higher event-free survivals compared to non-DS children using cytosine arabinoside (ara-C)/anthracycline-based protocols and a uniform presence of somatic mutations in the X-linked transcription factor gene, GATA1. Several chromosome 21-localized transcription factor oncogenes including ETS2 may contribute to the unique features of DS AMkL. ETS2 transcripts measured by real-time RT-PCR were 1.8-and 4.1-fold, respectively, higher in DS and non-DS megakaryoblasts than those in non-DS myeloblasts. In a doxycycline-inducible erythroleukemia cell line, K562pTet-on/ETS2, induction of ETS2 resulted in an erythroid to megakaryocytic phenotypic switch independent of GATA1 levels. Microarray analysis of doxycycline-induced and doxycycline-uninduced cells revealed an upregulation by ETS2 of cytokines (for example, interleukin 1 and CSF2) and transcription factors (for example, TAL1), which are key regulators of megakaryocytic differentiation. In the K562pTet-on/ ETS2 cells, ETS2 induction conferred differences in sensitivities to ara-C and daunorubicin, depending on GATA1 levels. These results suggest that ETS2 expression is linked to the biology of AMkL in both DS and non-DS children, and that ETS2 acts by regulating expression of hematopoietic lineage and transcription factor genes involved in erythropoiesis and megakaryopoiesis, and in chemotherapy sensitivities.
Introduction
Down syndrome (DS) children have a 10-to 20-fold increased risk of developing acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) compared to non-DS children. 1 AML in DS children displays unique characteristics including a predominance of the acute megakaryocytic leukemia (AMkL) phenotype, [2] [3] [4] [5] [6] [7] [8] [9] which is estimated to occur at a 500-fold greater frequency in DS children compared to non-DS children. 8 This suggests that trisomy 21 plays an important role in leukemogenesis. DS and non-DS children with AMkL treated with cytosine arabinoside (ara-C)/anthracycline-based protocols have extremely different treatment outcomes. DS children routinely experience event-free survival (EFS) rates of 80-100%, 1 whereas non-DS children with AMkL have extremely low EFS rates (o30%). These results highlight distinct biological differences between DS and non-DS AMkL cases. Consistent with this notion, in our previous studies using in vitro MTT assays, DS megakaryoblasts were significantly more sensitive to ara-C and daunorubicin than non-DS megakaryoblasts, 10 similar to results reported by others. 11, 12 Somatic mutations in exon 2 of the X-linked gene, GATA1, which encodes a zinc-finger transcription factor that is essential for normal erythroid and megakaryocytic differentiation, have been detected exclusively and almost uniformly in all DS AMkL cases, but not in non-DS AML or non-AMkL DS leukemia cases. [13] [14] [15] [16] [17] [18] [19] The net effect of the mutations is to introduce early stop codons that result in the synthesis of a shorter GATA1 (GATA1s, 40 kDa) protein translated from a downstream initiation site, distinguishable from the full-length 50-kDa GATA1 protein in its transactivation capacity. GATA1 mutations in DS are believed to cause accumulation of poorly differentiated megakaryocytic precursors. 13 The high frequency of the AMkL phenotype in DS AML and the extremely different treatment outcomes between DS and non-DS AMkLs suggest that interactions between chromosome 21-localized genes (present in three copies in trisomy 21 cells) and GATA1 mutations may facilitate the development of AMkL and may also be involved in the altered chemotherapy sensitivities between DS and non-DS AMkL. Candidate genes include transcription factor oncogenes located on chromosome 21, such as AML1, ERG and ETS2.
AML1 (also known as RUNX1, a DNA-binding subunit of the transcription complex termed core-binding factor 20, 21 ) is located in the 'critical Down syndrome region' on chromosome 21 and is an established regulator of hematopoiesis and megakaryopoiesis. [21] [22] [23] AML1 haploinsufficiency in humans impairs some aspect of megakaryopoiesis, as is also seen in mouse models. 22, 23 In humans, hereditary loss-of-function mutations of AML1 cause the autosomal dominant familial platelet disorder with a predisposition to develop AML. 23 Most recently, it was reported that transcripts for AML1b and AML1c, the two larger isoforms of AML1, are downregulated in DS megakaryoblasts compared to non-DS megakaryoblasts, suggesting that AML1 is linked to the megakaryocytic lineage. 24 In addition to its gene dosage effects, AML1 coexpresses and cooperates with GATA1 in megakaryocytic differentiation. 25 ETS2 and ERG (ETS transcription factor family members) have been shown to be overexpressed in adult myeloid leukemia cases with complex acquired karyotypes involving chromosome 21. 26 This suggests that these two genes may also play important roles in leukemogenesis in individuals with DS, since both genes are located on chromosome 21q22 within the minimal DS region. 27 Consistent with this hypothesis, forced expression of ERG3 results in a phenotypic switch from erythroid to megakaryocytic development 28 such that trisomy 21 may cause developmental skewing toward the megakaryocytic lineage during hematopoietic development. This 'promegakaryocytic pressure' may, in turn, enhance the selection and proliferation of hematopoietic progenitor cells with GATA1 mutations, leading to an arrest in differentiation.
28
ETS2 is ubiquitously expressed in adult tissues. In hematopoietic cells, ETS2 is abundantly expressed in monocytes and macrophages of the myeloid lineage but not in granulocytes, 29 and has been implicated in regulating megakaryocytic gene expression, 30 macrophage differentiation 31 and T-cell development. 32 Constitutive ETS2 expression transforms NIH 3T3 cells and makes them tumorigenic. 33 In prostate cancer, ETS2 is overexpressed 34 and its function is required to maintain the transformed state of human prostate cancer cells. 35 In this report, we show that transcript levels for ETS2 are significantly higher in megakaryoblasts from both DS and non-DS children with AMkL than those in myeloblasts from non-DS children with other AML subtypes. Furthermore, for the children with AMkL, median ETS2 transcripts tended to be higher in the non-DS AMkL cases than in the DS AMkL cases. These results suggest that ETS2 may play a critical role in the development of AMkL and in the differential chemotherapy sensitivities between DS and non-DS children with AMkL. By inducibly overexpressing ETS2 in a K562 cell line model, we show that ETS2 can result in a phenotypic switch from the erythroid to megakaryocytic lineage independent of GATA1 levels, and result in altered ara-C and daunorubicin sensitivities depending on GATA1 levels. Microarray studies revealed a modulation of critical transcription factors and cytokines by ETS2 in K562 cells, which may be responsible for the observed erythroid to megakaryocytic phenotypic switch and the altered chemotherapy drug sensitivities.
Materials and methods

Clinical samples
Diagnostic blast samples from DS children with AMkL (66% median blasts) and from non-DS children with AMkL (81.5% median blasts) or other subtypes of AML (84% median blasts) were obtained from the Children's Hospital of Michigan leukemia cell bank and from the Pediatric Oncology Group 9421 study, as previously described. 36, 37 The diagnosis of AMkL was confirmed by flow cytometric detection of the megakaryocytic lineage antigens, CD41 and CD61. Mononuclear cells were isolated on Ficoll-Hypaque gradients to obtain highly purified cell fractions consisting mostly of leukemic blasts. Total RNAs were extracted from the samples using TRIzol reagent (Invitrogen Life Technologies, Carlsbad, CA, USA). The research protocol was approved by the Human Investigation Committee of Wayne State University School of Medicine.
Cell culture
The DS AMkL cell line, CMK, was obtained from the German Collection of Microorganisms and Cell Cultures (DSMZ; Braunschweig, Germany). The CMY DS AMkL cell line (established from a 21-month-old DS boy with AMkL), the CTS non-DS AML cell line and the non-DS AMkL cell line, CMS, were gifts from Dr A Fuse (National Institute of Infectious Diseases, Tokyo, Japan). The K562 and KG-1a erythroleukemia cell lines, the U937 non-DS monocytic AML cell line, and the Meg-01 and Dami non-DS AMkL cell lines were obtained from the American Type Culture Collection (Manassas, VA, USA). All cell lines were cultured in RPMI 1640 with 10% calf bovine serum (Hyclone, Logan, UT, USA) and 2 mM L-glutamine plus 100 U ml À1 penicillin and 100 mg ml À1 streptomycin, in a 37 1C humidified atmosphere containing 5% CO 2 /95% air.
Expression of an inducible ETS2 construct in K562 cells
A commercial 'Tet-on' (Clontech, Palo Alto, CA, USA) system was used to express ETS2 in ETS2-null K562 cells under control of a tetracycline/doxycycline (Dox)-inducible promoter. 38 The K562pTet-on cell line was developed from wild-type K562 cells by transfection with the regulator pTet-on plasmid using Lipofectin (Invitrogen Life Technologies), as previously reported. 39 To construct the pTRE2hyg/ETS2 plasmid, wild-type ETS2 cDNA from CMK cells was PCR amplified with forward (5 0 -AACTCGGATCCGCAGCGGCAGGATGAATGATTTCGGA-3 0 ) and reverse (5 0 -AACTCCTCGAGGCTCAGGGTGGTCCCGGCGA CCTCAG-3 0 ) primers and cloned into the pTRE2hyg plasmid at the BamHI and SalI sites (underlined in the above primer sequences). The plasmid was then transfected into the K562pTet-on cell line by electroporation (200 V, 950 mF) and screened by selection with hygromycin (200 mg ml
À1
). Colonies were isolated in soft agar, expanded in the presence of 200 mg ml À1 hygromycin and tested for ETS2 expression in the presence or absence of Dox (2 mg ml À1 ) by western blotting, as described below. A 'double-stable' resistant clone (designated KE), which exhibited no background and a high level of Dox-induced ETS2 expression, was identified and used for further analysis.
siRNA knockdown experiments
The upper strand GATA1 small interfering RNA (siRNA) oligo (5 0 -GATCCGGACAGGCCACTACCTATGTTCAAGAGACATAG GTAGTGGCCTGTCCTTA-3 0 ) and the lower strand GATA1 siRNA oligo (5 0 -AGCTTAAGGACAGGCCACAACCTATGTCTCT TGAACATAGGTAGTGGCCTGTCCG-3 0 ) were annealed and cloned into pSliencer 4.1-CMV hygro (Ambion, Austin, TX, USA) digested with BamHI and HindIII. The resulting plasmid and a negative control pSilencer 4.1-CMV hygro vector that expressed a hairpin siRNA with limited homology to any known sequences in the human, mouse and rat genomes (Ambion) were transfected into the KE cells, respectively, by electroporation (200 V, 950 mF) and selected with a higher dose of hygromycin (400 mg ml
À1
) for 2 weeks. Colonies were isolated in soft agar, expanded in the presence of 400 mg ml À1 hygromycin and tested for GATA1 expression in the absence of Dox by Western blotting and real-time reverse transcription (RT)-PCR. One colony was selected and designated KE-G. A pool of cells from the negative control transfection (designated KE-Neg) were used as the negative control for the GATA1 siRNA stable clone.
Western blot analysis
Soluble protein extracts were prepared by sonication in hypotonic buffer (10 mM Tris-Cl, pH 7.0), containing 1% sodium dodecyl sulfate (SDS) and proteolytic inhibitors, and subjected to SDS-PAGE. Separated proteins were electrophoretically
The role of ETS2 in AMkL Y Ge et al transferred to polyvinylidene difluoride membranes (DuPont Biotechnology, Johnston, IA, USA) and immunoblotted with anti-ETS2 (C-20) or anti-GATA1 (N1) antibodies (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), as described previously. 37 Immunoreactive proteins were visualized using the Odyssey Infrared Imaging System (Li-Cor, Lincoln, NE, USA), as described by the manufacturer.
Flow cytometry analysis
To determine the extent of cell differentiation of the KE and KE-G cells induced by 2 mg ml À1 Dox, expression of cell surface markers was measured by flow cytometry. Briefly, suspension cultures of KE or KE-G cells induced with or without 2 mg ml À1 Dox were resuspended in phosphate-buffered saline (PBS) þ 30% adult bovine serum (Sigma Chemical Co., St Louis, MO, USA) at a concentration of 2 Â 10 6 cells per ml. Samples were stained in the dark at room temperature for 30 min with the following two-color cocktails, using the manufacturer's recommended concentrations: CD36-fluorescein isothiocyanate (FITC)/glycophorinA-PE, CD41-FITC/CD11b-PE, CD61-FITC/ CD33-PE and CD9-FITC/CD34-PE (Coulter/Immunotech, Brea, CA, USA). Appropriately matched isotype controls were used throughout. After staining, samples were washed in PBS, resuspended in PBS containing 0.25% formaldehyde and immediately analyzed on a Coulter XL-MCL flow cytometer equipped with an argon laser. Viable KE or KE-G cells were gated using forward and side scatter characteristics and analyzed for immunofluorescence patterns.
In vitro sensitivities of the KE-Neg and KE-G cells with or without Dox induction of ETS2
For determinations of cytotoxicities, the cell lines were cultured in complete medium with dialyzed fetal calf serum in 96-well plates at a density of 4 Â 10 4 cells per ml. Cells were cultured continuously with a range of ara-C and daunorubicin concentrations at 37 1C with or without 2 mg ml À1 Dox, and cell numbers were determined using the Cell Titer-blue reagent (Promega, Madison, WI, USA) and a fluorescence microplate reader. The IC 50 values were calculated as the concentrations of drug necessary to inhibit 50% growth compared to control cells cultured in the absence of drug. The data are presented as the mean values ± s.e. from at least three independent experiments.
Microarray sample preparation and hybridization
Prior to sample preparation, RNA quality was determined using an Agilent Bioanalyzer, Agilent Technologies, Santa Clara, CA, USA. Samples of total RNA were then amplified as aRNA while incorporating aminoallyl modified bases, using the TargetAMP 1-Round Aminoallyl-aRNA Amplification Kit 101 per the vendor's protocol (Epicentre, Madison, WI, USA). Five micrograms of each aminoallyl-aRNA sample were fluorescently labeled using Alexa 555 or 647 by incubating with an aminereactive dye conjugate for 1 h at room temperature. Unincorporated dye was removed using an RNeasy column (Qiagen, Valencia, CA, USA). Dye incorporation efficiency was determined using a Nanodrop spectrophotometer. Whole human genome oligonucleotide microarrays (Agilent Technologies, Santa Clara, CA, USA, catalog no. G4112A) were hybridized using 0.75 mg of Alexa 555 labeled aRNA and 0.75 mg of Alexa 647 labeled aRNA. Agilent's SureHyb hybridization chambers were used in a hybridization oven and rotation rack for 17 h at 60 1C. After hybridization, the slides were washed per Agilent's SSPE wash protocol.
Slides were scanned using an Agilent's dual laser scanner with PMT settings at 100%. Tiff images were analyzed with Agilent's feature extraction software (version 7.5). Local background subtraction and linear and LOWESS normalization were performed. The resultant data were analyzed using Rosetta Resolver (version 5.1, Rosetta Biosoftware). Features flagged as saturated in both channels or flagged as nonuniformity outliers in either channel were excluded from analysis.
On each microarray, a labeled ETS2 positive (induced) sample was cohybridized with an oppositely labeled ETS2 negative (uninduced) sample. Two arrays were completed for each of two independent pairs of biological samples, for a total of four microarrays. One pair was created from a sample taken prior to ETS2 induction and a sample obtained at the 24 h time point after ETS2 induction. An independent set of samples was similarly obtained using a 25 h time point. A dye-swapped pair of arrays was completed for each pair of biological samples.
Verification of gene expression by real-time RT-PCR
cDNAs were prepared from 1 mg RNA using random hexamer primers and a RT-PCR kit (Perkin Elmer Life Sciences, Boston, MA, USA), and purified with the QIAquick PCR Purification Kit (Qiagen). ETS2, T-cell acute lymphocytic leukemia 1 (TAL1), interleukin 1a (IL1A), interleukin 1b (IL1B), erythroblast membraneassociated protein (ERMAP), integrin a2b (ITGA2B), hemoglobin a2 (HBA2) and colony stimulating factor 2 (CSF2) transcripts were quantitated using a LightCycler real-time PCR machine (Roche, Indianaopolis, IN, USA), as previously described. 37 Briefly, PCR reactions contained 2 ml purified cDNA or standard plasmid, 4 mM MgCl 2 , 0.5mM each of sense and antisense primers and 2 ml FastStart DNA Master SYBR Green I enzyme-SYBR reaction mix (Roche). Primers and PCR conditions are described in Supplementary Table S1 . Real-time PCR results were expressed as mean values from three independent experiments using the same cDNA preparation and normalized to 18S rRNA.
Statistical analysis
Differences in transcript levels between the DS and non-DS AML patient groups were compared using the nonparametric Mann-Whitney two-sample test. Statistical analyses were performed with GraphPad Prism 4.0.
Results
Overexpression of ETS2 in both DS and non-DS megakaryoblasts compared to non-DS myeloblasts
DS AML cases have several unique features including a predominance of the megakaryocytic phenotype (490% of DS cases compared to an overall frequency of B10% for non-DS pediatric AML cases) and uniform presence of somatic GATA1 mutations in DS AMkL. [13] [14] [15] [16] [17] [18] [19] This suggests that trisomy 21 and GATA1 mutations cooperate to facilitate the development of AMkL in DS children. Overexpression of chromosome 21-localized transcription factor oncogenes including ERG, AML1 and ETS2 in DS may contribute to the megakaryocytic phenotype in DS leukemia cases. This hypothesis has been in part supported by studies from Rainis et al., 28 who showed that overexpression of ERG3 in K562 cells resulted in an erythroid to megakaryocytic phenotypic 'switch'.
Based on the gene dosage effect of three copies of chromosome 21 in DS cells, it is predicted that transcript levels for chromosome 21-localized genes including ETS2 would be 1.5-fold higher in DS AMkL compared to non-DS AMkL cases.
The 20) megakaryoblasts were significantly higher (1.8-fold, P ¼ 0.027) than those in non-DS AML blasts (n ¼ 52, excluding non-DS AMkL cases) (Figure 1a) . Interestingly, median ETS2 transcripts were also higher in non-DS AMkL cases (4.1-fold higher (P ¼ 0.013)) than those in non-DS AML blasts. Furthermore, there was an obvious trend toward higher median ETS2 transcript levels (2.3-fold, P ¼ 0.16) in the non-DS AMkL cases compared to the DS AMkL cases. However, this difference was not quite statistically significant, likely due to the sample size.
Analogous to primary patient samples, ETS2 transcript levels were also higher in DS (CMK, CMY) and non-DS AMkL (Meg-01, Dami, CMS) cell lines overall, compared to non-DS AML cell lines (KG1a, K562, U937, CTS) (Figure 1b) . Collectively, these results suggest that overexpression of ETS2 in AMkL relative to other subtype AMLs may play an important role in AMkL biology overall.
Inducible expression of ETS2 in K562 cells results in an erythroid to megakaryocytic phenotypic switch
To further investigate the role of ETS2 in AMkL, an ETS2 Doxinducible expression system, K562pTet-on/ETS2, was generated (designated KE) in the human erythroleukemia cell line, K562, which has potential to differentiate into either erythroid or megakaryocytic lineage cells. 40 When the KE cells were induced by 2 mg ml À1 Dox, ETS2 protein levels increased in a timedependent manner with the protein level peaking at 25 h (Figure 2a, upper panel) . To determine the optimal concentration of Dox, the KE cells were induced with a range of Dox concentrations for 24 h. Western blot analyses established 2 mg ml À1 to be the optimal concentration of Dox to induce the highest level of ETS2 protein in the cells (Figure 2a, lower  panel) .
To determine the effects of ETS2 on differentiation of K562 cells, the KE cells were induced with 2 mg ml À1 Dox for up to 120 h and subjected to flow cytometry analysis every 24 h to determine the expression levels for the megakaryocyte-specific cell surface antigens, CD41 and CD61, and the erythroid marker, glycophorin A. Induction of ETS2 coincided with increased expression of CD41 (Figure 2b ) and CD61 (Figure 2c) , and decreased glycophorin A expression (data not shown), compared to uninduced cells or mock transfectants (with or without induction). These results provide additional evidence of a linkage between ETS2 and AMkL, and support the notion of an erythroid to megakaryocytic phenotypic switch of K562 cells with increased ETS2 expression.
ETS2 induction on megakaryocytic differentiation of K562 cells may be GATA1-independent
To explore whether the effects of ETS2 on K562 cell differentiation were GATA1-dependent, siRNA silencing GATA1 expression was performed in the KE cells; the resulting cell lines were designated KE-Neg and KE-G, respectively. As shown in panels a and b of Figure 3 , stable expression of GATA1 siRNA in the KE cells resulted in B50% decrease of both GATA1 transcripts and protein compared to the KE-Neg cells expressing a nontarget negative control siRNA. Knockdown of GATA1 had at most only a minor effect on the inducible expression of ETS2 in the KE cells (Figure 3c ).
The effects of ETS2 induction on the expression of megakaryocytic surface markers were identical in the negative control KE-Neg cells (Figures 4a and b) and normal KE cells (Figure 2 ). GATA1 knockdown resulted in decreased expression of CD41 in the KE-G cells in the absence of ETS2 induction (Figures 4a and  c) . However, in spite of this, a decrease of GATA1 expression did not affect the induction of cell differentiation toward the megakaryocytic lineage accompanying ETS2 induction (Figures  4c and d) .
Determination of ETS2 target genes in K562 cells by microarray analysis
To identify genes potentially linked to the apparent erythroid to megakaryocytic phenotypic switch resulting from induced ETS2 expression in the K562 cells, oligonucleotide microarray analysis was performed on two independent pairs of total RNA samples isolated from induced (2 mg ml À1 Dox for 24 h) and uninduced KE cells. Average log ratios representing the The role of ETS2 in AMkL Y Ge et al difference in expression between ETS2-expressing and ETS2-null samples were derived for each array feature by combining the replicate array data, using the error-weighted algorithm of Rosetta Resolver. 41 Differentially expressed genes were identified by their P-values, calculated with the Resolver's errormodel and the replicate data. Features (probes) with a P-value p0.005 were considered statistically significant. Using this cutoff, 4505 features were identified as differentially expressed (data not shown). Given the P-value and the number of features on the array, approximately 205 features would be expected to have a significant P-value by chance (that is, false positives), indicating that the false discovery rate was very stringent at 4.6%. To further reduce false positives, we filtered the set of 4505 features to select only those having a minimum ± 1.5-fold change. This resulted in the identification of 1683 features that were used in our subsequent analysis (Supplementary Table S2 ). Figure 2 Development of the KE cell line and induction of an erythroid to megakaryocytic phenotypic switch with ETS2 expression. The erythroleukemia cell line, K562, was previously transfected with pTet-on to generate the K562pTet-on stable clone. 36 The K562pTet-on stable clone was then transfected with pTRE2hyg-ETS2 by electroporation (200 V, 950 mF) to generate the K562pTet-on/ETS2 stable clone (designated KE). ETS2 protein levels were assayed on western blots with an anti-ETS2 antibody. The time dependence with 2 mg ml À1 Dox (panel a, upper panel) and the Dox concentration dependence at 24 h (panel a, lower panel) for optimal induction of ETS2 expression in the KE cells were determined. In panels b and c, the KE cells were induced by 2 mg ml À1 Dox for up to 120 h and subjected to flow cytometry analysis of megakaryocytic cell surface markers (CD41 and CD61, respectively) every 24 h, as described in Materials and methods. ) for 2 weeks. Colonies were isolated in soft agar, expanded in the presence of 400 mg ml À1 hygromycin, tested for GATA1 expression in the absence of Dox by real-time reverse transcription (RT)-PCR (panel a) and western blotting (panel b). One colony was chosen and designated KE-G. A pool of cells from the negative control transfection (designated KE-Neg) was used as the negative control of the GATA1 siRNA stable clone. siRNA knockdown of GATA1 had only a minor impact on the inducible expression of ETS2 in the KE-G cells compared to the KE-Neg cells (panel c).
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Verification of microarray data by real-time RT-PCR
To validate the differentially expressed genes identified by microarrays, real-time RT-PCR was used with the same RNA samples used in the microarray analyses from induced and uninduced KE cells. Several representative genes from the microarray analysis (Supplementary Table S2 ) associated with a switch from an erythroid to a megakaryocytic phenotype were either under-or overexpressed in the induced KE cells relative to the uninduced cells. ERMAP (NM_018538) and HBA2 (NM_000517) genes were chosen from the underexpressed group, and ETS2, ITGA2B (platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41B; NM_000419), TAL1 (NM_003189), IL1A (NM_000575), IL1B (NM_000576) and granulocyte-macrophage CSF2 (NM_000758) genes were selected from the upregulated group. Our real-time RT-PCR results (Figure 5a ) indicate that the differences in transcript levels for ERMAP, HBA2, ITGA2B, ETS2, IL1A, IL1B, CSF2 and TAL1 were all statistically significant between the induced and uninduced KE cells, consistent with our microarray data. When expression patterns were determined in a time course experiment (Figure 5b ), gene expression levels (lower panel) paralleled changes in ETS2 protein levels (upper panel).
ETS2 modulates hematopoietic lineage genes and transcriptional regulator genes in K562 cells
Among the 1683 probes differentially expressed between induced and uninduced KE cells identified by microarray was a group of hematopoietic lineage genes including membrane metalloendopeptidase (antigen CD10), integrin a4 (ITGA4, antigen CD49D), CD36 (oxidized fatty acid transporter, thrombospondin receptor), CD33 (siglec-3; sialic acid-binding immunoglobin-like lectin), ITGA2B (antigen CD41B), integrin b3 (ITGB3, antigen CD61), IL1A, IL1B and CSF2 (Table 1) . Interestingly, ETS2 differentially regulates a large group of transcriptional regulators in the K562 cells (Supplementary Table S3 ). Of these transcriptional regulators, TAL1, Kruppel-like factor 1 (erythroid, KLF1, also known as EKLF) and nuclear factorerythroid 2 (NFE2) are known to be critical regulators of erythropoiesis or megakaryopoiesis.
These results further confirm the erythroid to megakaryocytic phenotypic switch of K562 cells accompanying ETS2 induction. Upregulation of cytokines (for example, IL1 and CSF2) and modulation of transcription factor genes (for example, TAL1 and KLF1) by ETS2 in K562 cells may provide a molecular basis for the phenotypic switch resulting from ETS2 overexpression. Implication of cooperation between ETS2 and GATA1 in sensitivities of ara-C and daunorubicin
Studies from our group and others have demonstrated that DS megakaryoblasts are significantly more sensitive in vitro to both ara-C and daunorubicin, the two main drugs used in the treatment of AML, compared to non-DS megakaryoblasts and non-DS myeloid blasts. [10] [11] [12] This indicates that chromosome 21-localized genes somehow contribute to these unique patterns of drug activity. The uniform detection of GATA1 exon 2 mutations in DS AMkL implies that GATA1 mutations and loss of GATA1 function for GATA1s may also be involved in the enhanced drug sensitivities in DS AMkL. This is suggested by our findings of increased resistance to ara-C and daunorubicin accompanying stable overexpression of GATA1 in the DS AMkL cell line, CMK. 37 It is also possible that chromosome 21-localized genes (for example, ETS2) may interact with GATA1s protein to modulate ara-C and daunorubicin sensitivities in DS AMkL.
To explore the relationship between levels of ETS2 and GATA1 and chemotherapy sensitivity of AMkL, growth inhibitions by ara-C and daunorubicin were determined in the KE-Neg and KE-G cells with or without Dox induction of ETS2. In the KE-Neg cells, induction of ETS2 resulted in threefold increased ara-C sensitivity compared to uninduced cells. (Figure 6a ). However, in the KE-G cells with decreased GATA1 levels (compared to the KE-Neg cells), induction of ETS2 was accompanied by decreased ara-C drug sensitivity (Figure 6b) . Interestingly, reduced GATA1 expression in the absence of ETS2 overexpression is functionally neutral in this system ( Figure 6 ). Analogous results were obtained with daunorubicin in the KE-Neg and KE-G cells (data not shown). These findings strongly imply that ETS2 and GATA1 functionally cooperate so as to determine ara-C and daunorubicin sensitivities in KE-G cells, and by extension to AMkL.
Discussion
In the present study, we demonstrated that ETS2, a member of the ETS transcription factor family, may play a critical role in the biology of AMkL, analogous to the ERG gene. 28 Real-time RT-PCR analysis established that median ETS2 transcripts were overexpressed in both DS and non-DS AMkL cases compared to other subtypes of AML cases. Interestingly, for the children with AMkL, there was a clear trend toward higher median ETS2 transcripts (median 2.3-fold) in the non-DS AMkL cases For determinations of cytotoxicities, the cell lines were cultured in complete medium with dialyzed fetal calf serum in 96-well plates at a density of 4 Â 10 4 cells per ml. Cells were cultured continuously with a range of cytosine arabinoside (ara-C) concentrations at 37 1C with or without 2 mg ml À1 Dox and cell numbers were determined using the Cell Titer-blue reagent (Promega) and a microplate reader. The IC 50 values were calculated as the concentrations of drug necessary to inhibit 50% growth compared to control cells cultured in the absence of drug. The data are presented as the mean values ± s.e. from at least three independent experiments. By paired t-test, the differences in ara-C IC 50 for induced and uninduced cells were statistically significant.
The role of ETS2 in AMkL Y Ge et al compared to the DS AMkL cases, in spite of the differences in gene dosage. This is analogous to another chromosome 21-localized gene, AML1, which was downregulated in DS AMkL compared to non-DS AMkL. 24 Using an inducible expression system in K562 cells, we found that overexpression of ETS2 was associated with increased expression of the megakaryocytic cell surface markers, CD41 and CD61, independent of GATA1 levels. This suggests that ETS2 may play important roles in the AMkL phenotype in both DS and non-DS children. By microarray and real-time RT-PCR analyses, we found that ETS2 overexpression in K562 cells was associated with increased expression of megakaryopoiesisassociated cytokines, such as IL1A, IL1B and CSF2, involved in early maturation of megakaryocytes, and with altered expression of transcription factors important for erythropoiesis and megakaryopoiesis, such as TAL1, KLF1 and NF-E2.
IL1 is an important cytokine mediator of many immunologic and inflammatory responses during bacterial infection, as well as proliferative and reconstructive responses during wound healing. 42 CSF2 is a cytokine that stimulates proliferation, differentiation and function of myeloid progenitor cells.
43
IL1 and CSF2 enhance megakaryocytic colonies in vitro, 43 suggesting that IL1 and CSF2 may play important roles in megakaryocytic differentiation.
TAL1 is a member of the basic helix-loop-helix family of transcription factors, 44 which plays an essential role in early hematopoiesis and megakaryopoiesis. [44] [45] [46] Increased expression of TAL1 accompanying induction of ETS2 in the KE cells may be another critical contribution to the megakaryocytic differentiation. KLF1 (or EKLF) is a zinc-finger transcription factor that plays very important roles in erythropoiesis by regulating the b-globin gene. [47] [48] [49] In the KE cells, overexpression of ETS2 significantly repressed KLF1 expression (Supplementary  Table S3 ), followed by decreased transcript levels for b-globin (Supplementary Table S2 ). Thus, ETS2 overexpression can repress erythropoiesis by downregulating KLF1. NFE2 is a bZIP transcription factor expressed in erythroid, megakaryocytic and mast cells, which is critical for production of platelets, the final process of megakaryocyte maturation, by regulating its target gene, b-tubulin. 50 Interestingly, NFE2 is downregulated in the KE cells upon induction of ETS2 (Supplementary Table S3 ), followed by decreased expression of b-tubulin (Supplementary Table S2) . Therefore, elevated expression of ETS2 may impair the terminal differentiation of megakaryocytes and affect production of platelets through downregulation of NFE2 and b-tubulin.
The significantly enhanced in vitro sensitivity to chemotherapy drugs (ara-C and daunorubicin) in DS megakaryoblasts compared to non-DS megarkyoblasts 10 suggests that trisomy 21 and GATA1 mutations may somehow cooperate to modulate chemotherapy drug activity toward DS megakaryoblasts. However, this has not been previously tested. In the present study, we found that silencing GATA1 while simultaneously overexpressing ETS2 resulted in decreased sensitivity to chemotherapy drugs. While the molecular basis for this surprising result is unclear, it nonetheless implies that GATA1 and ETS2 are functionally intertwined so as to modulate ara-C and daunorubicin sensitivities. Indeed, the increased resistance to ara-C and daunorubicin resulting from induction of ETS2 in the KE-G cell line model suggests that elevated ETS2 may actually be an unfavorable determinant of chemotherapy sensitivity in DS AMkL. This would be minimized by the downregulation of ETS2 in DS AMkL compared to non-DS AMkL, as implied by our results in a small number of AMkL patient specimens. Of course, validation of this hypothesis will require further experiments in appropriate DS AMkL cell line models to identify the complex mechanisms responsible for the significantly enhanced chemotherapy sensitivities in DS AMkL compared to non-DS AMkL. 10 In summary, our results with KE and KE-G cell line models suggest that ETS2 likely contributes to the AMkL phenotype in both DS and non-DS children. Furthermore, an apparent cooperation between ETS2 and GATA1 was implied that results in significantly altered sensitivities to chemotherapy drugs used for AMkL, such as ara-C and daunorubicin.
